450
Participants
Start Date
June 1, 2024
Primary Completion Date
June 1, 2025
Study Completion Date
June 1, 2026
Plasma exchange
Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Daratumumab
Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
RECRUITING
Brigham and Women's Hospital, Boston
Janssen, LP
INDUSTRY
Baystate Health
OTHER
Boston Medical Center
OTHER
Dana-Farber Cancer Institute
OTHER
Massachusetts General Hospital
OTHER
Mayo Clinic
OTHER
M.D. Anderson Cancer Center
OTHER
Medical University of South Carolina
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Northwell Health
OTHER
Ochsner Health System
OTHER
Ohio State University
OTHER
Stanford University
OTHER
Texas Medical Center
UNKNOWN
Thomas Jefferson University
OTHER
University of Alabama at Birmingham
OTHER
University of California, Los Angeles
OTHER
University of Chicago
OTHER
University of Colorado Health
OTHER
University of Minnesota
OTHER
University of New Mexico
OTHER
University of Pennsylvania
OTHER
University of Pittsburgh
OTHER
University of Virginia
OTHER
University of Washington
OTHER
Brigham and Women's Hospital
OTHER